Bischlorethylnitrosourea
Bischlorethylnitrosourea Brand names, Bischlorethylnitrosourea Analogs
Bischlorethylnitrosourea Brand Names Mixture
- No information avaliable
Bischlorethylnitrosourea Chemical_Formula
C5H9Cl2N3O2
Bischlorethylnitrosourea RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Bischlorethylnitrosourea fda sheet
Bischlorethylnitrosourea msds (material safety sheet)
Bischlorethylnitrosourea Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Bischlorethylnitrosourea Molecular Weight
214.049 g/mol
Bischlorethylnitrosourea Melting Point
31 oC
Bischlorethylnitrosourea H2O Solubility
< 0.1 g/100 mL at 18 °C
Bischlorethylnitrosourea State
Solid
Bischlorethylnitrosourea LogP
1.256
Bischlorethylnitrosourea Dosage Forms
Powder for solution; Wafer
Bischlorethylnitrosourea Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Bischlorethylnitrosourea Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Bischlorethylnitrosourea Absorption
5 to 28% bioavailability
Bischlorethylnitrosourea side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Bischlorethylnitrosourea Patient Information
No information avaliable
Bischlorethylnitrosourea Organisms Affected
Humans and other mammals
